Article
XPO1 is a new target of homoharringtonine (HHT): Making NPMc+ AML cells much more sensitive to HHT treatment.
Biochemical and biophysical research communications - 1 Oct 2023
Xue Jingjing, Chu Peng, Gao Wenjuan, Wang Furong, Gao Yuan, Liu Shuqing, Kang Zhijie, Yan Jinsong, Wang Haina
Abstract excerpt
Acute myeloid leukemia (AML) is a heterogeneous disease and about one third of AML patients carry nucleophosmin (NPM1) mutation. Because 95% mutations give NPM1 an additional nuclear export signaling (NES) and dislocate NPM1 in cytoplasm (NPMc+), relocating NPM1 in nucleus provide an innovative strategy for treating this type of AML. The nuclear export of NPM1 depends on the nuclear protein export receptor XPO1,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.